Sharma R*, Gulati A, Chopra K*. Accelerated approvals in oncology: Trial design strategies and insights driving successful regulatory outcomes across three decades. Int J Cancer. 2025 Dec 29. doi: 10.1002/ijc.70317. Epub ahead of print. PMID: 41460153.
Sharma R*, Gulati A, Chopra K. Era of surrogate endpoints and accelerated approvals: a comprehensive review on applicability, uncertainties, and challenges from regulatory, payer, and patient perspectives. Eur J Clin Pharmacol. 2025 May;81(5):605-623. doi: 10.1007/s00228-025-03822-w. Epub 2025 Mar 13. PMID: 40080138.
Sharma R*, Goulding R, Franklin M. Evaluation of the Use of Surrogate Outcomes in Oncology Clinical Trials. Value in Health, Volume 25, Issue 7, S333
Kanters S, Wilkinson L, Vrazic H, Sharma R, et al. Comparative efficacy of once-weekly semaglutide versus SGLT-2 inhibitors in patients inadequately controlled with one to two oral antidiabetic drugs: a systematic literature review and network meta-analysis. BMJ Open 2019;9:e023458. doi: 10.1136/bmjopen-2018-023458
Sharma R, Wilkinson L, Vrazic H, Popoff E, Lopes S, Kanters S and Druyts E. Comparative efficacy of once-weekly semaglutide and SGLT-2 inhibitors in type 2 diabetic patients inadequately controlled with metformin monotherapy: a systematic literature review and network meta-analysis. Curr Med Res Opin. 2018;1-9. doi: 10.1080/03007995.2018.1476332.
Yan K, Balijepalli C, Sharma R, Barakat S, Sun SX, Falcao S, Druyts E, and FitzGerald JM. Reslizumab and mepolizumab for moderate-to-severe poorly controlled asthma: an indirect comparison meta-analysis. Immunotherapy. 2019; https://doi.org/10.2217/imt-2019-0113
Sharma R, Koruth RM, Kanters S, Druyts E and Tarhini A. Comparative efficacy and safety of dabrafenib plus trametinib versus competing adjuvant therapies for high-risk melanoma. . Journal of Comparative Effectiveness Research. 2019; https://doi.org/10.2217/cer-2019-0061; ahead of print.
Sharma R, Kaundal RK, Sharma SS. Targeting inflammation by PPAR-gamma agonist in LPS induced pulmonary dysfunction. Indian Journal of Pharmacology 2008; 40(2):S151 http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3086159/
Sharma R and Sharma SS. Targeting Inflammation in COPD – Hope or Hype. Current Research & Information on Pharmaceutical Sciences 2008;9 (2):22-26 http://www.niper.nic.in/targetting.pdf
Sharma R, Kumar A, Sharma SS. Respiratory Safety Pharmacology. Current Research & Information on Pharmaceutical Sciences. 2007;8 (1):13-16
Koruth R, Sharma R, Kanters S and Druyts E. Establishing the relationship between relapse-free survival and overall survival in adjuvant high-risk radically resected cutaneous melanoma. (2019), SMR Congress 2018 Abstracts. Pigment Cell Melanoma Res, 32:129.
Koruth R, Sharma R, Kanters S and Druyts E. Dabrafenib and trametinib combination versus other interventions for advanced cutaneous melanoma: a network meta-analysis. (2019), SMR Congress 2018 Abstracts. Pigment Cell Melanoma Res, 32:126.
Sharma R, Cheung A, Bolzani A, Barakat S, Sun SX, Druyts E and FitzGerald JM. Comparative efficacy of reslizumab and mepolizumab for the treatment of asthma: A network meta-analysis. Value in Health 2016; 19 (7):A549
Sharma R, Arora M, Ubhadiya B. Impact of placebo run-in period on relative treatment effect in Generalized Anxiety Disorder (GAD). Value in Health 2010; 13 (7):A459 http://onlinelibrary.wiley.com/doi/10.1111/j.1524-4733.2010.00791_2.x/pdf
Sharma R, Kaundal RK, Sharma SS. Amelioration of pulmonary dysfunction and neutrophilic inflammation by PPARγ agonist in LPS exposed guinea pigs. Pulmonary Pharmacology and Therapeutics 2009;22:183–189 .http://www.sciencedirect.com/science/article/pii/S1094553908001314